Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of comorbidity scores and lifestyle factors in curative radiotherapy in laryngeal cancer

Z. Pechacova, R. Lohynska, M. Pala, T. Drbohlavova, T. Korinek

. 2023 ; 199 (10) : 881-890. [pub] 20230412

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24001187

Grantová podpora
BUH, IN 00064211 Ministerstvo Zdravotnictví Ceské Republiky

E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2006-08-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 1997-01-01 do Před 1 rokem

Odkazy

PubMed 37042973
DOI 10.1007/s00066-023-02072-y
Knihovny.cz E-zdroje

PURPOSE: The principal goal of treatment of laryngeal cancer is to eliminate a tumour while preserving laryngeal function with radio(chemo)therapy being the mainstay of treatment. The aim of this report is to present the influence of comorbidities and lifestyle factors on treatment outcomes in our cohort of patients. METHODS: During the period 2009-2018, curative radio(chemo)therapy for laryngeal cancer was performed on 189 patients. RESULTS: The median OS was 50.8 months, with a mean PFS of 96.5 months, mean LC of 101.4 months and a median follow-up of 38.1 months. Acute and late treatment toxicity grade 3-4 was observed in 39.2% patients and 10.1% patients, respectively. A significant effect on overall survival was confirmed for the baseline PS (performance status), severity of weight loss, baseline haemoglobin values, history of alcohol abuse, marital status and comorbidities according to the Charlson Comorbidity Index, as well as the ACE-27 and ASA scores. CONCLUSIONS: In our cohort of patients treated with radio(chemo)therapy for laryngeal cancer, we found good therapeutic results and an acceptable side-effect profile. Statistically significant predictors of overall survival were the baseline PS, weight loss, anaemia, associated comorbidities, history of alcohol abuse and marital status.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001187
003      
CZ-PrNML
005      
20240213094423.0
007      
ta
008      
240109s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00066-023-02072-y $2 doi
035    __
$a (PubMed)37042973
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Pechacova, Zdenka $u Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Bulovka University Hospital, Budinova 67/2, 18081, Prague, Czech Republic. zdenka.pechacova@bulovka.cz $1 https://orcid.org/0000000262929814
245    10
$a Impact of comorbidity scores and lifestyle factors in curative radiotherapy in laryngeal cancer / $c Z. Pechacova, R. Lohynska, M. Pala, T. Drbohlavova, T. Korinek
520    9_
$a PURPOSE: The principal goal of treatment of laryngeal cancer is to eliminate a tumour while preserving laryngeal function with radio(chemo)therapy being the mainstay of treatment. The aim of this report is to present the influence of comorbidities and lifestyle factors on treatment outcomes in our cohort of patients. METHODS: During the period 2009-2018, curative radio(chemo)therapy for laryngeal cancer was performed on 189 patients. RESULTS: The median OS was 50.8 months, with a mean PFS of 96.5 months, mean LC of 101.4 months and a median follow-up of 38.1 months. Acute and late treatment toxicity grade 3-4 was observed in 39.2% patients and 10.1% patients, respectively. A significant effect on overall survival was confirmed for the baseline PS (performance status), severity of weight loss, baseline haemoglobin values, history of alcohol abuse, marital status and comorbidities according to the Charlson Comorbidity Index, as well as the ACE-27 and ASA scores. CONCLUSIONS: In our cohort of patients treated with radio(chemo)therapy for laryngeal cancer, we found good therapeutic results and an acceptable side-effect profile. Statistically significant predictors of overall survival were the baseline PS, weight loss, anaemia, associated comorbidities, history of alcohol abuse and marital status.
650    _2
$a lidé $7 D006801
650    12
$a nádory hrtanu $x patologie $7 D007822
650    12
$a alkoholismus $x etiologie $7 D000437
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a chemoradioterapie $x škodlivé účinky $7 D059248
650    _2
$a komorbidita $7 D015897
650    _2
$a životní styl $7 D008019
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lohynska, Radka $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Pala, Miloslav $u Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Bulovka University Hospital, Budinova 67/2, 18081, Prague, Czech Republic
700    1_
$a Drbohlavova, Tereza $u Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Bulovka University Hospital, Budinova 67/2, 18081, Prague, Czech Republic
700    1_
$a Korinek, Tomas $u National Radiation Protection Institute, Prague, Czech Republic $u Military University Hospital, Prague, Czech Republic
773    0_
$w MED00010658 $t Strahlentherapie und Onkologie $x 1439-099X $g Roč. 199, č. 10 (2023), s. 881-890
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37042973 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213094420 $b ABA008
999    __
$a ok $b bmc $g 2049659 $s 1210881
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 199 $c 10 $d 881-890 $e 20230412 $i 1439-099X $m Strahlentherapie und Onkologie $n Strahlenther Onkol $x MED00010658
GRA    __
$a BUH, IN 00064211 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace